Brn2/POU3F2 (D2C1L) Rabbit mAb #12137
- WB
- IP
- IF
- ChIP
- C&R
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 55 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
- ChIP-Chromatin Immunoprecipitation
- C&R-CUT & RUN
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
The CUT&RUN dilution was determined using CUT&RUN Assay Kit #86652.
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| Immunofluorescence (Frozen) | 1:1600 - 1:3200 |
| Chromatin IP | 1:50 |
| Chromatin IP-seq | 1:50 |
| CUT&RUN | 1:50 |
Storage
For a carrier free (BSA and azide free) version of this product see product #35173.
Protocol
Specificity / Sensitivity
Brn2/POU3F2 (D2C1L) Rabbit mAb recognizes endogenous levels of total Brn2/POU3F2 protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human Brn2/POU3F2 protein.
Background
Brn2/POU3F2 is a POU domain-containing transcription factor involved in neuronal differentiation and activation of the corticotrophin-releasing hormone gene (1,2). In mice, disruption of the Brn2 gene results in loss of specific neuronal lineages in the hypothalamus (3). In addition to its role in mammalian neurogenesis, Brn2 has also been implicated in melanoma tumorigenesis and has been shown in the literature to be overexpressed in human melanoma cells compared to normal melanocytes (4,5). Recent studies also identify Brn2 as a transcription factor playing an important role in keratinocyte differentiation (6). Recent reports demonstrate that overexpression of three transcription factors (Brn2, Ascl1, and Myt1L) can directly convert human fibroblasts into functional neurons under precisely defined conditions (7,8).
- Fujii, H. and Hamada, H. (1993) Neuron 11, 1197-206.
- Schonemann, M.D. et al. (1995) Genes Dev 9, 3122-35.
- Nakai, S. et al. (1995) Genes Dev 9, 3109-21.
- Cook, A.L. et al. (2003) J Invest Dermatol 121, 1150-9.
- Cook, A.L. and Sturm, R.A. (2008) Pigment Cell Melanoma Res 21, 611-26.
- Shi, G. et al. (2010) PLoS One 5, e13216.
- Pfisterer, U. et al. (2011) Proc Natl Acad Sci USA 108, 10343-8.
- Ambasudhan, R. et al. (2011) Cell Stem Cell 9, 113-8.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.